KALA Key Statistics, Chart & Performance
The current stock price of KALA is 0.964 USD. In the past month the price increased by 26.46%. In the past year, price decreased by -85.8%.
KALA Latest News, Press Relases and Analysis
KALA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.2 | 404.22B | ||
| AMGN | AMGEN INC | 15.55 | 183.17B | ||
| GILD | GILEAD SCIENCES INC | 14.97 | 152.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.35 | 116.04B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.06 | 75.97B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 912.43 | 61.48B | ||
| INSM | INSMED INC | N/A | 43.73B | ||
| NTRA | NATERA INC | N/A | 33.41B | ||
| BIIB | BIOGEN INC | 10.87 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.85B | ||
| INCY | INCYTE CORP | 15.65 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About KALA
Company Profile
Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Company Info
KALA BIO INC
1167 Massachusetts Avenue
Arlington MASSACHUSETTS 02472 US
CEO: Mark Iwicki
Employees: 38
Phone: 17819965252
KALA BIO INC / KALA FAQ
What does KALA do?
Kala Bio, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 38 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
Can you provide the latest stock price for KALA BIO INC?
The current stock price of KALA is 0.964 USD. The price increased by 4.22% in the last trading session.
Does KALA BIO INC pay dividends?
KALA does not pay a dividend.
How is the ChartMill rating for KALA BIO INC?
KALA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of KALA BIO INC (KALA)?
KALA BIO INC (KALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.72).
Can you provide the upcoming earnings date for KALA BIO INC?
KALA BIO INC (KALA) will report earnings on 2026-03-30, after the market close.
What is the ownership structure of KALA BIO INC (KALA)?
You can find the ownership structure of KALA BIO INC (KALA) on the Ownership tab.
KALA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KALA. When comparing the yearly performance of all stocks, KALA is a bad performer in the overall market: 99.69% of all stocks are doing better.
KALA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KALA. Both the profitability and financial health of KALA have multiple concerns.
KALA Financial Highlights
Over the last trailing twelve months KALA reported a non-GAAP Earnings per Share(EPS) of -5.72. The EPS increased by 54.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -73.89% | ||
| ROE | -624.6% | ||
| Debt/Equity | 2.65 |
KALA Forecast & Estimates
7 analysts have analysed KALA and the average price target is 1.53 USD. This implies a price increase of 58.71% is expected in the next year compared to the current price of 0.964.